CTA
ICPT

Carillon Tower Advisers’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Carillon Tower Advisers’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-196,877
Closed -$9.43M – 498
2020
Q2 		$9.43M Buy
+196,877
New +$15.2M 0.07% 300
2019
Q1 		– Sell
-202,771
Closed -$20.4M – 476
2018
Q4 		$20.4M Buy
+202,771
New +$21M 0.17% 213

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Carillon Tower Advisers's ICPT Position: Q3 2020 in Review

Carillon Tower Advisers sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2020, closing a stake of 196,877 shares — an estimated $9.43M sold.

Carillon Tower Advisers first reported a position in ICPT in Q4 2018 and held it in 2 quarters. The position peaked at $20.4M in Q4 2018. 177 funds tracked by Wall St. Rank hold ICPT as of Q3 2020.

  • Carillon Tower Advisers reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Carillon Tower Advisers sold 196,877 Intercept Pharmaceuticals, Inc. shares in Q3 2020, an estimated $9.43M.
  • Carillon Tower Advisers first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2018 and held it in 2 quarters.
  • Carillon Tower Advisers's Intercept Pharmaceuticals, Inc. position peaked at $20.4M in Q4 2018.
  • 177 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2020.

Based on Carillon Tower Advisers's 13F filing for Q3 2020, filed 12 Nov 2020.